Mani Mohindru Acquires 24,703 Shares of Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) CEO Mani Mohindru bought 24,703 shares of the stock in a transaction on Thursday, June 18th. The stock was purchased at an average price of $1.21 per share, for a total transaction of $29,890.63. Following the completion of the purchase, the chief executive officer owned 24,703 shares of the company’s stock, valued at approximately $29,890.63. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cardiff Oncology Trading Up 10.3%

Shares of CRDF stock traded up $0.12 on Monday, hitting $1.33. 510,986 shares of the stock were exchanged, compared to its average volume of 1,109,367. The firm’s 50 day moving average is $1.63 and its two-hundred day moving average is $1.97. Cardiff Oncology, Inc. has a one year low of $1.16 and a one year high of $4.55. The firm has a market capitalization of $91.27 million, a PE ratio of -1.98 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. On average, sell-side analysts expect that Cardiff Oncology, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRDF has been the subject of a number of recent analyst reports. Craig Hallum lowered Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday, June 3rd. HC Wainwright cut shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler lowered their target price on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, TD Cowen downgraded shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.75.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors have recently made changes to their positions in CRDF. Bank of America Corp DE lifted its holdings in shares of Cardiff Oncology by 23.9% during the 1st quarter. Bank of America Corp DE now owns 51,119 shares of the company’s stock worth $83,000 after acquiring an additional 9,855 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Cardiff Oncology during the first quarter valued at about $164,000. Sei Investments Co. bought a new stake in Cardiff Oncology during the first quarter worth about $89,000. Virtu Financial LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter worth about $108,000. Finally, XTX Topco Ltd boosted its holdings in shares of Cardiff Oncology by 40.5% in the 4th quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock worth $616,000 after purchasing an additional 63,196 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.